manilatimes5h
Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI® In Germany
~ PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, ...
Malaysian Reserve6h
Most patients on Lilly’s Omvoh® (mirikizumab-mrkz) for Crohn’s disease achieved sustained clinical remission and endoscopic response at two years
More than 90% of Omvoh-treated patients who were in clinical remission at one year sustained it with two years of continuous treatment Nearly 90% of ...
Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI In Germany
PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin Chemotherapy in Patients 1 month to ~ Norgine Pharmaceutica ...
eLife18h
Intrinsic bioenergetic adaptations compensate for reduced mitochondrial content in HER2-driven mammary tumors
However, mechanistic studies to support the conclusion that mitochondrial function is increased in the tumours remain incomplete and would benefit from experiments that would directly interrogate ...